- Conditions
- Healthy Volunteers
- Interventions
- SHP681, Placebo
- Drug · Other
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 104 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Knoxville, Tennessee
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Postprandial Hypoglycemia
- Interventions
- Exendin-(9-39), Vehicle
- Drug · Other
- Lead sponsor
- Diva De Leon
- Other
- Eligibility
- 6 Months to 18 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Obesity
- Interventions
- Exenatide, Normal saline .2cc subcutaneous injection
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Tirzepatide, Dulaglutide
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 13,299 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 121
- States / cities
- Birmingham, Alabama • Concord, California • Covina, California + 106 more
- Conditions
- Insulin Secretion
- Interventions
- GIP infusion, GLP-1 infusion, Ex-9 infusion
- Drug
- Lead sponsor
- David D'Alessio, M.D.
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Obesity, Weight Change Trajectory, Weight Change, Body
- Interventions
- Revita Duodenal Mucosal Resurfacing (DMR), Sham
- Device
- Lead sponsor
- Fractyl Health Inc.
- Industry
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 315 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Newport Beach, California + 24 more
- Conditions
- Obesity, Overweight or Obesity
- Interventions
- MET097, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 239 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- Anaheim, California • Hollywood, Florida
- Conditions
- Polycystic Ovarian Syndrome in Adolescent Females, Obesity (Disorder)
- Interventions
- GLP-1 Receptor Agonists
- Drug
- Lead sponsor
- Nemours Children's Clinic
- Other
- Eligibility
- 12 Years to 18 Years · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Healthy Participants
- Interventions
- Glucagon, Control Study
- Biological · Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Overweight and Obesity
- Interventions
- 24-hour ambulatory blood pressure, Liberal salt diet
- Diagnostic Test · Dietary Supplement
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Diabetes Mellitus, Type 2, Cardiovascular Diseases
- Interventions
- Educational Intervention
- Other
- Lead sponsor
- Humana Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 4,197 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Diabetes Mellitus
- Interventions
- To utilize the FreeStyle Libre 3 Continuous Glucose Monitoring System (FSL3) to help prolong the length of time people with diabetes maintain adherence to GLP-1 and dual GIP/GLP-1 agonists
- Device
- Lead sponsor
- Abbott Diabetes Care
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- Jacksonville, Florida • Miami Gardens, Florida
- Conditions
- Health, Wellness, Quality of Life
- Interventions
- A ready-to-mix beverage containing protein, fiber, and electrolytes
- Dietary Supplement
- Lead sponsor
- PepsiCo Global R&D
- Industry
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 133 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Del Mar, California
- Conditions
- PreDiabetes
- Interventions
- Exendin 9-39, Saline
- Biological
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 25 Years to 70 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Type 1 Diabetes
- Interventions
- Xeris glucagon, Lilly glucagon
- Drug
- Lead sponsor
- Steven J. Russell, MD, PhD
- Other
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Obesity
- Interventions
- Glucagon, Placebo
- Drug
- Lead sponsor
- AdventHealth Translational Research Institute
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2027
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Type 1 Diabetes, Insulin Sensitivity/Resistance
- Interventions
- GLP-1, Insulin, Dextrose 20 % in Water
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years to 40 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Glucagon-Like Peptide- 1 (GLP-1) infusion, Placebo Comparator: Saline Infusion
- Drug · Other
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2026
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Lixisenatide (AVE0010), Placebo, Pen auto-injector, Sulfonylurea, Metformin
- Drug · Device
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 859 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Obesity, Skeletal Muscle
- Interventions
- Exercise training, Semaglutide
- Behavioral · Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 50 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Hypoglycemia
- Interventions
- Exendin (9-39), Placebo
- Drug · Other
- Lead sponsor
- Tracey McLaughlin
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2014
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Triglycerides, Weight Gain Trajectory, Cholesterol, Elevated
- Interventions
- RDX-002, Placebo
- Drug
- Lead sponsor
- Response Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Saint Paul, Minnesota
- Conditions
- Type 1 Diabetes
- Interventions
- Bi-homonal Bionic Pancreas, Usual care
- Device · Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Obesity & Overweight, Weight Loss, Preventative Health, Body Weight, Cardiovascular Disease Risk Factor
- Interventions
- Noom Weight, Free Tier, Education-only control, Semaglutide, Tirzepatide, Microdose semaglutide, Microdose tirzepatide
- Behavioral · Drug
- Lead sponsor
- Noom Inc.
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 2,310 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey